Navigation Links
Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
Date:11/2/2012

pies, and to evaluate the effects of the combination therapies on TG and other lipids and lipoproteins.

About Epanova™Epanova is a patent protected, novel, ultra-pure mixture of the free fatty acid forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Omthera has developed a substantial body of data on Epanova, which points to an improved and more predictable bioavailability as compared to the ethyl ester form found in prescription Omega-3 products currently available. Triglyceride lowering with Epanova was previously observed in two large, placebo-controlled, randomized, double-blind, Phase III studies involving 748 Crohn's disease patients with normal triglyceride levels for >/= 52 weeks, approximately 400 of which were treated with Epanova for remission of disease. In all studies performed to date, Epanova has demonstrated a very good safety and tolerability profile.

About HypertriglyceridemiaHypertriglyceridemia refers to a condition in which patients have high blood levels of triglycerides and is associated with increased risk of heart disease. It is one component of a range of lipid disorders collectively referred to as dyslipidemia. The overall dyslipidemia population in the U.S. is believed to be in excess of 100 million, with approximately 40 million of those diagnosed with hypertriglyceridemia (triglycerides greater than 200mg/dL) and an estimated 4 million with very high triglyceride levels (triglycerides greater than 500mg/dL). Very high triglycerides are associated with an increased risk of pancreatitis. Regulatory approval for the treatment of very high triglycerides is based on a significant reduction in the serum triglyceride levels.

About Omthera Pharmaceuticals, Inc.Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately held, specialty pharmaceutical company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... MADISON HEIGHTS, Mich. , March 4, 2015 /PRNewswire/ ... national provider of infusion pumps and related services for ... issue fourth quarter and full year 2014 financial results ... The Company will also conduct a conference ... 4:30 p.m. Eastern Time to discuss fourth quarter and ...
(Date:3/4/2015)... WASHINGTON , March 4, 2015  Mail-service ... consumers, employers and government health plans ... research released by the Pharmaceutical Care Management Association ... specialty drugs offers one of the easiest ways ... CEO Mark Merritt . "Policymakers should resist ...
(Date:3/4/2015)... , March 4, 2015   Mayo Clinic ... agreement to develop the next generation of wearable biosensors ... are hoping that this technology will be game-changer. These ... diabetes," says James Levine, M.D., Ph.D. , a ... are accurate, inexpensive, and can be integrated into the ...
Breaking Medicine Technology:PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Illinois Employers, Consumers and Public Programs by $11.8 Billion 2Mayo Clinic and Gentag, Inc. Announce Agreement To Develop Wireless Sensors for Treatment of Obesity and Diabetes 2Mayo Clinic and Gentag, Inc. Announce Agreement To Develop Wireless Sensors for Treatment of Obesity and Diabetes 3
... Accuray Incorporated (Nasdaq: ARAY ), a global ... accepted abstracts highlighting the use of the CyberKnife Robotic Radiosurgery ... 52nd Annual Meeting of the American Society for Radiation Oncology ... Presentations related to CyberKnife radiosurgery cover a ...
... HSIC ), the largest provider of healthcare products ... for the quarter ended September 25, 2010. Net ... an increase of 14.1% compared with the third quarter of ... a decline of 2.3% related to foreign currency exchange.  Internal ...
Cached Medicine Technology:Accuray's CyberKnife VSI System Featured at 2010 American Society for Radiation Oncology (ASTRO) Annual Meeting 2Accuray's CyberKnife VSI System Featured at 2010 American Society for Radiation Oncology (ASTRO) Annual Meeting 3Accuray's CyberKnife VSI System Featured at 2010 American Society for Radiation Oncology (ASTRO) Annual Meeting 4Henry Schein Reports Record Third Quarter Results 2Henry Schein Reports Record Third Quarter Results 3Henry Schein Reports Record Third Quarter Results 4Henry Schein Reports Record Third Quarter Results 5Henry Schein Reports Record Third Quarter Results 6Henry Schein Reports Record Third Quarter Results 7Henry Schein Reports Record Third Quarter Results 8Henry Schein Reports Record Third Quarter Results 9Henry Schein Reports Record Third Quarter Results 10Henry Schein Reports Record Third Quarter Results 11
(Date:3/4/2015)... (PRWEB) March 04, 2015 Dr. Christopher ... NuMale Medical Center today lamented the FDA’s recent ... therapy (TRT). He argued that FDA’s conclusions are ... harm men who suffer from testosterone deficiency. , “The ... equivocation” on testosterone replacement therapy,” said Dr. Asandra. “There ...
(Date:3/4/2015)... Austria (PRWEB) March 04, 2015 ... reduce subjectivity in density assessment and help improve ... of numerous abstracts accepted for presentation at the ... 2015. Ten abstracts - eight posters and ... Volpara Solutions’ automated breast density and quantitative breast ...
(Date:3/4/2015)... 2015 Starting February 2015, Dr. Joseph ... procedures at their new location in Surrey. , In ... and Dr. Gabriel Chu also provide comprehensive ophthalmology services, ... named Fraser Valley Cataract and Laser (FVCL). This state ... College of Physicians and Surgeons of British Columbia. Fraser ...
(Date:3/4/2015)... Georgia (PRWEB) March 04, 2015 State ... part of the School of Public Health at Georgia ... The funds were awarded by Georgia’s Division of Family ... to support the DFCS Call Center. , The ... maltreatment by providing information and referral services that promote ...
(Date:3/4/2015)... La Farge, Wis. (PRWEB) March 04, 2015 ... a leading organic brand, today announced its cause campaign to ... has gone viral and is making a difference to Bros ... million views on Youtube and Facebook. The video was ... and was featured in Forbes, Mashable and Digiday, among other ...
Breaking Medicine News(10 mins):Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:King LASIK relocates to Surrey, British Columbia 2Health News:State Funds Child Abuse Helpline Housed At Georgia State 2Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 2Health News:ORGANIC VALLEY URGES PUBLIC TO SAVE THE BROs: CAMPAIGN EARNS MORE THAN 1M VIEWS ON YOUTUBE 3
... for treatment of Human Immunodeficiency Virus type 1 ... of combination therapy in 1996//. More recently, new ... and improved safety profiles, while some previously popular ... drawbacks become better defined. Resistance testing is used ...
... Bill Ledger, of Sheffield University has developed a test, which ... woman has left//. ,The test, which is expected ... fertility is dropping off. The development has been hailed to ... give women the same control over their fertility as the ...
... of Oxford, UK has found a new theory from the ... administered world wide for children’s to prevent// from Tuberculosis infection ... with TB infection. The researchers studied the risk factors involved ... had BCG scar, as the absence of BCG scar implies ...
... teeth and gums are photosensitive says an article published ... The paper authored by a researcher at Washington University// ... is an important factor in the maintenance of oral ... to oral health," observed study author Charles F. Hildebolt, ...
... (ED) is the inability of a man to achieve or ... needs of his partner. Most men experience this at some ... not psychologically affected by it. Some men, however, experience chronic, ... ,According to a new study in the October 18 ...
... fish has been proved with evidence following the finding that ... of three to four years. The research adds to the ... sharp//. ,Previous findings have established that consumption of ... Alzheimer’s disease and stroke. Fish such as salmon and tuna ...
Cached Medicine News:Health News:Simplest therapeutic regimen found less effective against HIV 2Health News:Women can now gauge their own future fertility 2Health News:BCG vaccine for both Protection and treatment of Tuberculosis 2Health News:Sunlight For Healthy Gums And Teeth 2Health News:Erectile dysfunction: an early warning sign of clinically silent coronary artery disease? 2
... fixed pipette is ideal for ... volume. Fixed volume FInnpipettes offer ... as other Finnpipette Digital pipettes: ... blow-out (1-40ul), Soft-touch tip ejection, ...
500L...
... ergonomics, and value!, Comfortable feel ... non-slip, contoured handle , Finer control ... spring action , Completely autoclavable for ... need for recalibration , Easy-to-read precision ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Medicine Products: